KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Payables (2016 - 2025)

Novartis Ag's Payables history spans 14 years, with the latest figure at $5.1 billion for Q4 2025.

  • On a quarterly basis, Payables fell 1.46% to $5.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 billion, a 1.46% decrease, with the full-year FY2025 number at $5.1 billion, down 1.46% from a year prior.
  • Payables hit $5.1 billion in Q4 2025 for Novartis Ag, up from $4.5 billion in the prior quarter.
  • Over the last five years, Payables for NVS hit a ceiling of $6.5 billion in Q4 2021 and a floor of $4.1 billion in Q2 2024.
  • Historically, Payables has averaged $5.2 billion across 5 years, with a median of $5.2 billion in 2024.
  • Biggest five-year swings in Payables: fell 22.5% in 2024 and later grew 8.68% in 2025.
  • Tracing NVS's Payables over 5 years: stood at $6.5 billion in 2021, then decreased by 6.87% to $6.0 billion in 2022, then dropped by 7.64% to $5.6 billion in 2023, then dropped by 6.05% to $5.2 billion in 2024, then decreased by 1.46% to $5.1 billion in 2025.
  • Business Quant data shows Payables for NVS at $5.1 billion in Q4 2025, $4.5 billion in Q2 2025, and $5.2 billion in Q4 2024.